RecruitingNot ApplicableNCT06088212

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor: the Cog-HF Trial

Sponsor

Baker Heart and Diabetes Institute

Enrollment

168 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Heart Failure Cognitive Change Cognitive Impairment Dementia Cognitive Decline Left Ventricular Dysfunction

Summary

This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether intensive management of heart failure can also help protect and improve brain function in older patients who show signs of cognitive impairment (memory and thinking problems) after a heart failure hospitalization. Researchers believe better heart health management may be a way to prevent or slow mental decline. **You may be eligible if...** - You were hospitalized with heart failure as a primary or secondary diagnosis - You showed at least mild cognitive impairment (based on a MoCA test) at hospital discharge - Your cognitive impairment persists at a 2-week follow-up check **You may NOT be eligible if...** - You are unable to give written consent - You are receiving palliative or end-of-life care - You are already in another randomized clinical trial - You have a terminal illness (such as cancer) that may affect your prognosis over the next 12 months - Your cognitive function recovered quickly after discharge (MoCA score above 25 at 2-week recheck) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDisease management program

The components of our DMP include: 1. Intensive post-discharge education 2. Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer. 3. Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period. 4. Exercise program delivered by an exercise physiologist 5. Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly.